🇺🇸 FDA
Pipeline program

MT-401-OTS

MRKR-21-401-OTS

Phase 1 small_molecule active

Quick answer

MT-401-OTS for Acute Myeloid Leukemia, in Relapse is a Phase 1 program (small_molecule) at Marker Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Marker Therapeutics
Indication
Acute Myeloid Leukemia, in Relapse
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials